Body composition phenotypes in IPF and their association with clinical outcomes

<bold>Introduction:</bold> Malnutrition and sarcopenia in idiopathic pulmonary fibrosis (IPF) negatively affect quality of life (QoL). We investigated body composition phenotypes and their association with clinical outcomes in IPF. <bold>Methods:</bold> In 68 IPF patients, body composition, muscle strength, and exercise capacity were assessed to determine the phenotypes, and the relationship of the results with pharmacologic treatment, and QoL. <bold>Results:</bold> Table 1 displays the patients' demographics and clinical results. The body composition phenotypes are presented in Table 2. BMI (body mass index) was shown to be correlated with SGRQ (St. George Respiratory Questionnaire), MEP(max expiratory pressure), HG(handgrip), and serum albumin level; FFM(fat-free mass) to mMRC (modified Medical Research Council), SGRQ, MIP(max inspiratory pressure), MEP, and HG; and FFMI(FFM index) to SGRQ, MEP, and HG. <bold>Conclusions:</bold> These results revealed that the majority of IPF patients were not underweight, the risk of sarcopenia was lower in overweight and obese patients, BMI and FFMI were not significantly different in those who did not use antifibrotics. It has been demonstrated that not only BMI but also FFM should be incorporated in IPF evaluations to reach therapeutic goals such as dyspnea perception and improved QoL. <table-wrap><object-id>erj;64/suppl_68/PA5175/T1</object-id><object-id>T1</object-id><object-id>t1</object-id><label>Table 1:</label><caption> Demographic Data and Results </caption><table><colgroup><col></col><col></col></colgroup><tbody><tr><td></td><td> Mean±SD</td></tr><tr><td>Gender m/f, n(%)</td><td>57(83.8)/11(16.2)</td></tr><tr><td>Age(year)</td><td>61,85±9.72</td></tr><tr><td>Nintedanib/Pirfenidone/non-medication users n(%)</td><td>14(20.6)/23(33.8)/31(45.6)</td></tr><tr><td>BMI</td><td>27,11±5.1</td></tr><tr><td>FFM</td><td>53,46±10.0</td></tr><tr><td>FFMI</td><td>19,54±2.3</td></tr><tr><td>SGRQ</td><td>58,52±25.6</td></tr><tr><td>MIP(cmH2O)</td><td>89,56±34.1</td></tr><tr><td>MEP(cmH2O)</td><td>113,87±38.9</td></tr><tr><td>HG</td><td>30,24±10.4</td></tr></tbody></table></table-wrap> <table-wrap><object-id>erj;64/suppl_68/PA5175/T2</object-id><object-id>T2</object-id><object-id>t2</object-id><label>Table 2:</label><caption> Body Composition Phenotypes </caption><table><colgroup><col></col><col></col><col></col></colgroup><tbody><tr><td></td><td>Males</td><td>Females</td></tr><tr><td>Cachexia</td><td>2</td><td>−</td></tr><tr><td>Sarcopenia</td><td>12</td><td>−</td></tr><tr><td>Normal</td><td>6</td><td>3</td></tr><tr><td>Non-sarcopenic obesity</td><td>14</td><td>3</td></tr><tr><td>Sarcopenic obesity</td><td>−</td><td>−</td></tr></tbody></table></table-wrap>